If you are headed to BioCentury Inc.‘s BioEquity Europe Conference and are interested in learning how ImmunoScape is working toward the development of TCR-based therapies against solid tumors, send us a message. Our Co-founder and VP of Innovation Michael Fehlings will be on the ground and will be setting up meetings.
ImmunoScape presents at the 24th BioEquity Europe 2024
